We are live on
!
Find out more
ImmunityBio
IBRX
IBRX
276 hedge funds and large institutions have $339M invested in ImmunityBio in 2025 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 99 increasing their positions, 65 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
67% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 27
52% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 65
5% more funds holding
Funds holding: 262 → 276 (+14)
2.06% more ownership
Funds ownership: 15.14% → 17.2% (+2.1%)
4% less capital invested
Capital invested by funds: $352M → $339M (-$13.4M)
32% less call options, than puts
Call options by funds: $6.46M | Put options by funds: $9.55M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
276
Holders Change
+14
Holders Change %
+5.34%
% of All Funds
3.36%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
45
Increased
99
Reduced
65
Closed
27
Calls
$6.46M
Puts
$9.55M
Net Calls
-$3.09M
Net Calls Change
-$2.32M
Top Buyers
| 1 |
BlackRock
New York
|
+$13.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$11.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.6M |
| 4 |
Goldman Sachs
New York
|
+$11.4M |
| 5 |
Two Sigma Investments
New York
|
+$4.78M |
